SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Blueprint Medicines Corporation - BPMCNewsfile Corp • 07/11/22
Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billionMarket Watch • 06/30/22
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty PharmaPRNewsWire • 06/30/22
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic MastocytosisPRNewsWire • 06/09/22
Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?Zacks Investment Research • 06/02/22
Blueprint Medicines Corporation (BPMC) CEO Kate Haviland on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022PRNewsWire • 04/26/22
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung CancerPRNewsWire • 04/08/22
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic MastocytosisPRNewsWire • 03/25/22
Blueprint Medicines (BPMC) Down 9.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/18/22
Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022PRNewsWire • 03/08/22
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader TherapiesPRNewsWire • 02/28/22
Blueprint Medicines' (BPMC) CEO Jeff Albers on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/16/22
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/09/22